<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39438493</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>Broad cross neutralizing antibodies against sarbecoviruses generated by SARS-CoV-2 infection and vaccination in humans.</ArticleTitle><Pagination><StartPage>195</StartPage><MedlinePgn>195</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">195</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-024-00997-8</ELocationID><Abstract><AbstractText>The outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV-1), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 highlight the need for countermeasures to prevent future coronavirus pandemics. Given the unpredictable nature of spillover events, preparing antibodies with broad coronavirus-neutralizing activity is an ideal proactive strategy. Here, we investigated whether SARS-CoV-2 infection and vaccination could provide cross-neutralizing antibodies (nAbs) against zoonotic sarbecoviruses. We evaluated the cross-neutralizing profiles of plasma and monoclonal antibodies constructed from B cells from coronavirus disease 2019 (COVID-19) convalescents and vaccine recipients; against sarbecoviruses originating from bats, civets, and pangolins; and against SARS-CoV-1 and SARS-CoV-2. We found that the majority of individuals with natural infection and vaccination elicited broad nAb responses to most tested sarbecoviruses, particularly to clade 1b viruses, but exhibited very low cross-neutralization to SARS-CoV-1 in both natural infection and vaccination, and vaccination boosters significantly augmented the magnitude and breadth of nAbs to sarbecoviruses. Of the nAbs, several exhibited neutralization activity against multiple sarbecoviruses by targeting the spike receptor-binding domain (RBD) and competing with angiotensin-converting enzyme 2 (ACE2) binding. SCM12-61 demonstrated exceptional potency, with half-maximal inhibitory concentration (IC<sub>50</sub>) values of 0.001-0.091 μg/mL against tested sarbecoviruses; while VSM9-12 exhibited remarkable cross-neutralizing breadth against sarbecoviruses and SARS-CoV-2 Omicron subvariants, highlighting the potential of these two nAbs in combating sarbecoviruses and SARS-CoV-2 Omicron subvariants. Collectively, our findings suggest that vaccination with an ancestral SARS-CoV-2 vaccine, in combination with broad nAbs against sarbecoviruses, may provide a countermeasure for preventing further sarbecovirus outbreaks in humans.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hu</LastName><ForeName>Yabin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0382-4817</Identifier><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, 423000, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wu</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0009-0003-5273-6722</Identifier><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chang</LastName><ForeName>Fangfang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Xiaoyue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Northwest A&amp;F University, Yangling, 712100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qijie</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>The Central Hospital of Shaoyang, Shaoyang, 422099, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Shishan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Yongchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Xingyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>You</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Zhanpeng</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Northwest A&amp;F University, Yangling, 712100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Fen</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Tianyi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Chanfeng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Yinggen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, 510080, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hongying</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8258-0683</Identifier><AffiliationInfo><Affiliation>College of Life Sciences, Northwest A&amp;F University, Yangling, 712100, China. chenhy@nwsuaf.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Wenpei</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-4624-2879</Identifier><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China. wenpeiliu_2008@foxmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Translational Medicine Institute, The First People's Hospital of Chenzhou, Hengyang Medical School, University of South China, Chenzhou, 423000, China. wenpeiliu_2008@foxmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yi-Ping</ForeName><Initials>YP</Initials><AffiliationInfo><Affiliation>Institute of Human Virology, Zhongshan School of Medicine, and Key Laboratory of Tropical Disease Control of Ministry of Education, Sun Yat-sen University, Guangzhou, 510080, China. lyiping@mail.sysu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Xiaowang</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-8135-7292</Identifier><AffiliationInfo><Affiliation>College of Basic Medical Sciences, Hengyang Medical School, University of South China &amp; MOE Key Lab of Rare Pediatric Diseases, Hengyang, 421001, China. quxiaowang@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>92269115</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country /></Grant><Grant><GrantID>82102365</GrantID><Agency>National Natural Science Foundation of China (National Science Foundation of China)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438493</ArticleId><ArticleId IdType="pmc">PMC11496711</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00997-8</ArticleId><ArticleId IdType="pii">10.1038/s41541-024-00997-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Peiris, J. S. et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet361, 1319–1325 (2003).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7112372</ArticleId><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris, J. S., Guan, Y. &amp; Yuen, K. Y. Severe acute respiratory syndrome. Nat. Med.10, S88–S97 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7096017</ArticleId><ArticleId IdType="pubmed">15577937</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579, 270–273 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature579, 265–269 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, N. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med382, 727–733 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko, M., Seifert, S. N., Olival, K. J., Plowright, R. K. &amp; Munster, V. J. Bat-borne virus diversity, spillover and emergence. Nat. Rev. Microbiol18, 461–471 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289071</ArticleId><ArticleId IdType="pubmed">32528128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Aravena, M. et al. Ecology, evolution and spillover of coronaviruses from bats. Nat. Rev. Microbiol20, 299–314 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8603903</ArticleId><ArticleId IdType="pubmed">34799704</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan, Y. et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science302, 276–278 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao, K. et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature583, 286–289 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32380510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam, T. T. et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature583, 282–285 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32218527</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau, S. K. et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl Acad. Sci. USA102, 14040–14045 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1236580</ArticleId><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu, B. et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog.13, e1006698 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5708621</ArticleId><ArticleId IdType="pubmed">29190287</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix, A. et al. Genetic diversity of coronaviruses in bats in Lao PDR and Cambodia. Infect., Genet. Evol.: J. Mol. Epidemiol. Evolut. Genet. Infect. Dis.48, 10–18 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106194</ArticleId><ArticleId IdType="pubmed">27932284</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, W. et al. Bats are natural reservoirs of SARS-like coronaviruses. Science310, 676–679 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rihtaric, D., Hostnik, P., Steyer, A., Grom, J. &amp; Toplak, I. Identification of SARS-like coronaviruses in horseshoe bats (Rhinolophus hipposideros) in Slovenia. Arch. Virol.155, 507–514 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7087122</ArticleId><ArticleId IdType="pubmed">20217155</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouilh, M. A. et al. SARS-Coronavirus ancestor’s foot-prints in South-East Asian bat colonies and the refuge theory. Infect., Genet. Evol.: J. Mol. Epidemiol. Evolut. Genet. Infect. Dis.11, 1690–1702 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106191</ArticleId><ArticleId IdType="pubmed">21763784</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong, S. et al. Detection of novel SARS-like and other coronaviruses in bats from Kenya. Emerg. Infect. Dis.15, 482–485 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2681120</ArticleId><ArticleId IdType="pubmed">19239771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge, X. Y. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature503, 535–538 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389864</ArticleId><ArticleId IdType="pubmed">24172901</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, H. et al. A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein. Curr. Biol.30, 2196–2203.e2193 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7211627</ArticleId><ArticleId IdType="pubmed">32416074</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, H. et al. Identification of novel bat coronaviruses sheds light on the evolutionary origins of SARS-CoV-2 and related viruses. Cell184, 4380–4391.e4314 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8188299</ArticleId><ArticleId IdType="pubmed">34147139</ArticleId></ArticleIdList></Reference><Reference><Citation>Menachery, V. D. et al. SARS-like WIV1-CoV poised for human emergence. Proc. Natl Acad. Sci. USA113, 3048–3053 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4801244</ArticleId><ArticleId IdType="pubmed">26976607</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang, X. L. et al. Isolation and Characterization of a Novel Bat Coronavirus Closely Related to the Direct Progenitor of Severe Acute Respiratory Syndrome Coronavirus. J. Virol.90, 3253–3256 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810638</ArticleId><ArticleId IdType="pubmed">26719272</ArticleId></ArticleIdList></Reference><Reference><Citation>Menachery, V. D. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med21, 1508–1513 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4797993</ArticleId><ArticleId IdType="pubmed">26552008</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, N. et al. Serological Evidence of Bat SARS-Related Coronavirus Infection in Humans, China. Virol. Sin.33, 104–107 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6178078</ArticleId><ArticleId IdType="pubmed">29500691</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, H. et al. Human-animal interactions and bat coronavirus spillover potential among rural residents in Southern China. Biosaf. Health1, 84–90 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7148670</ArticleId><ArticleId IdType="pubmed">32501444</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy, P. D. &amp; Simon, A. E. New insights into the mechanisms of RNA recombination. Virology235, 1–9 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9300032</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe, C. L. et al. Generation of coronavirus spike deletion variants by high-frequency recombination at regions of predicted RNA secondary structure. J. Virol.71, 6183–6190 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC191880</ArticleId><ArticleId IdType="pubmed">9223514</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv, H. et al. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep.31, 107725 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7231734</ArticleId><ArticleId IdType="pubmed">32426212</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, D. E. et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg. microbes Infect.9, 900–902 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241448</ArticleId><ArticleId IdType="pubmed">32380903</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell184, 1858–1864.e1810 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7871851</ArticleId><ArticleId IdType="pubmed">33631096</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobben, M. et al. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Elife10, 10.7554/eLife.70330 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610423</ArticleId><ArticleId IdType="pubmed">34812143</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan, C. W. et al. Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors. N. Engl. J. Med385, 1401–1406 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422514</ArticleId><ArticleId IdType="pubmed">34407341</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, J. Z. et al. Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses. Nat. Commun.13, 6285 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9586968</ArticleId><ArticleId IdType="pubmed">36271047</ArticleId></ArticleIdList></Reference><Reference><Citation>Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science369, 731–736 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299279</ArticleId><ArticleId IdType="pubmed">32540900</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr, T. N. et al. SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature597, 97–102 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282883</ArticleId><ArticleId IdType="pubmed">34261126</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature597, 103–108 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9341430</ArticleId><ArticleId IdType="pubmed">34280951</ArticleId></ArticleIdList></Reference><Reference><Citation>Jette, C. A. et al. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. Cell Rep.36, 109760 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8423902</ArticleId><ArticleId IdType="pubmed">34534459</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez, D. R. et al. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Sci. Transl. Med14, eabj7125 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8899823</ArticleId><ArticleId IdType="pubmed">34726473</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, P. et al. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerg. Microbes Infect.11, 147–157 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8725896</ArticleId><ArticleId IdType="pubmed">34836485</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, Y. J. et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science375, 449–454 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400459</ArticleId><ArticleId IdType="pubmed">34990214</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, L. et al. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Sci. Transl. Med14, eabn6859 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017343</ArticleId><ArticleId IdType="pubmed">35438546</ArticleId></ArticleIdList></Reference><Reference><Citation>He, W. T. et al. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nat. Immunol.23, 960–970 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10083051</ArticleId><ArticleId IdType="pubmed">35654851</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, X. et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat. Microbiol7, 1063–1074 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35773398</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegu, A. et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science373, 1372–1377 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691522</ArticleId><ArticleId IdType="pubmed">34385356</ArticleId></ArticleIdList></Reference><Reference><Citation>Widge, A. T. et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N. Engl. J. Med384, 80–82 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727324</ArticleId><ArticleId IdType="pubmed">33270381</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemet, I. et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N. Engl. J. Med386, 492–494 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8823651</ArticleId><ArticleId IdType="pubmed">34965337</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science375, 678–680 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9836206</ArticleId><ArticleId IdType="pubmed">35040667</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science369, 643–650 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7299281</ArticleId><ArticleId IdType="pubmed">32540902</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreano, E. et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell184, 1821–1835.e1816 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7901298</ArticleId><ArticleId IdType="pubmed">33667349</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreer, C. et al. Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients. Cell182, 843–854.e812 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7355337</ArticleId><ArticleId IdType="pubmed">32673567</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch, F. et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature607, 128–134 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9259484</ArticleId><ArticleId IdType="pubmed">35447027</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko, M., Marzi, A. &amp; Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol5, 562–569 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. Q. et al. A SARS-CoV-2-Related Virus from Malayan Pangolin Causes Lung Infection without Severe Disease in Human ACE2-Transgenic Mice. J. Virol.97, e0171922 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9972989</ArticleId><ArticleId IdType="pubmed">36688655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, H. F. et al. Characterization of a mouse-adapted strain of bat severe acute respiratory syndrome-related coronavirus. J. Virol.97, e0079023 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10537601</ArticleId><ArticleId IdType="pubmed">37607058</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton, D. R. &amp; Topol, E. J. Variant-proof vaccines - invest now for the next pandemic. Nature590, 386–388 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33558746</ArticleId></ArticleIdList></Reference><Reference><Citation>Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. &amp; Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol.21, 626–636 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351583</ArticleId><ArticleId IdType="pubmed">34373623</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, M. et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct. Target Ther.7, 146 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9062866</ArticleId><ArticleId IdType="pubmed">35504917</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders, K. O. et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature594, 553–559 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8528238</ArticleId><ArticleId IdType="pubmed">33971664</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez, D. R. et al. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science373, 991–998 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8899822</ArticleId><ArticleId IdType="pubmed">34214046</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, M. Q. et al. Inactivated SARS-CoV-2 Vaccine Shows Cross-Protection against Bat SARS-Related Coronaviruses in Human ACE2 Transgenic Mice. J. Virol.96, e0016922 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9044931</ArticleId><ArticleId IdType="pubmed">35343762</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science373, 1109–1116 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268357</ArticleId><ArticleId IdType="pubmed">34344823</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. Cell Discov.8, 36 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9021188</ArticleId><ArticleId IdType="pubmed">35443747</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifert, S. N. et al. An ACE2-dependent Sarbecovirus in Russian bats is resistant to SARS-CoV-2 vaccines. PLoS Pathog.18, e1010828 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9498966</ArticleId><ArticleId IdType="pubmed">36136995</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, H. et al. Isolation of ACE2-dependent and -independent sarbecoviruses from Chinese horseshoe bats. J. Virol.97, e0039523 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10537568</ArticleId><ArticleId IdType="pubmed">37655938</ArticleId></ArticleIdList></Reference><Reference><Citation>He, R. et al. SARS-CoV-2 spike-specific T(FH) cells exhibit unique responses in infected and vaccinated individuals. Signal Transduct. Target Ther.8, 393 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10558553</ArticleId><ArticleId IdType="pubmed">37802996</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, J. et al. Identification of broad neutralizing antibodies against Omicron subvariants from COVID-19 convalescents and vaccine recipients. Virol. Sin.38, 313–316 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9850840</ArticleId><ArticleId IdType="pubmed">36682433</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, J. et al. Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals. Nat. Microbiol6, 51–58 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33199863</ArticleId></ArticleIdList></Reference><Reference><Citation>Wardemann, H. &amp; Busse, C. E. Expression Cloning of Antibodies from Single Human B Cells. Methods Mol. Biol.1956, 105–125 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30779032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>